"Because of the large volume of orders in urgent need of continuous scheduling, we arranged on the fifth of the first day of the first line of staff to start working one after another, the vacation arrangements have also made flexible adjustments, and make every effort to sprint to the annual order target!"
Ltd. (hereinafter referred to as "Littell"), located in Nanjing Jiangning Development Zone, outside the tablet workshop on the 3rd floor of Building B, Zhang Xiang, deputy manager of the production department, lamented that this year, the production line on the busy light, earlier than in any previous year.
It is reported that after more than eight years of construction, Littell, which was founded in 2012, was wholly acquired by Nanjing Fangshenghe Pharmaceutical Technology Co.Thus, the integrated operation mode of "R&D+Production" was started.Today, Littell has hundreds of employees, more than 20 independent products and commissioned products in total, and has developed into a national high-tech enterprise.
Zhang Xiang, who has been working in Littell for nearly 4 years, used to be able to take a full Spring Festival vacation record was broken this year - not only came to work early on the fifth day, but also rested for only 1 day until now.
He said Fong Sang Woo's development of Yixintan (i.e., sacubitril valsartan sodium tablets, a drug for high blood pressure and heart failure)It is the first generic drug of Sacubitril valsartan sodium tablets in China to break through the patent barriers and be legally marketed in advance.In the fourth quarter of last year for the first time "walked" off the Ritalin production line 200mg size of a heart Tan.It is also the only Sacubitril valsartan sodium tablet of this specification in the domestic market other than the original drug.This move will greatly reduce the cost of medication for patients with hypertension and heart failure, and better help health insurance control.
"In order to adapt to the production demand of Yixintan, we have been making preparations in advance since the second half of last year, recruiting more than 20 new front-line employees and investing nearly 10 million yuan to optimize and upgrade the workshop's original equipment to enhance production capacity."
In the tablet pressing workshop behind Zhang Xiang, the tablet presses on both sides of the exit are constantly "spitting" out white tablets, which are orderly transferred to the coating workshop for the next process along the curved pipeline. In other workshops, the production line is also running efficiently, and the front-line employees are operating in an orderly manner, working closely with the automated equipment, presenting a busy scene of full steam ahead.
Zhang Xiang said that Yixintan's weekly capacity at Littell has now been raised to 3 million tablets. "But that's not enough, and we have to find ways to boost it again."
The same as Zhang Xiang feel extraordinarily busy, but also Littell deputy general manager Chen Ning. "In the fourth quarter of last year, our production volume of Yixintan was less than 10 million tablets. By this year, our production schedule has doubled several times in the first quarter and is still surging in the second quarter ......"Pointing to the commercialization capacity measurement table on the computer, Chen Ning detailed the subsequent production plan.
Current capacity of 3 million tablets per week
How to further enhance
to meet the production schedule?
Chen Ning has a good idea about this. "At present, our production scheduling for a shift system, then we intend to gradually adjust to the two-shift system, to improve the efficiency of the use of equipment. In addition, we also intend to increase the coating machine, granulator and other key equipment, on the one hand, can meet the production demand of existing orders, on the other hand, is also to prepare for next year." Next year's order volume is also expected to have a sizable increase, he said.
Chen Ning's prediction stems from Yixintan's continuously rising market size.
It is reported that, due to the clear mechanism of efficacy, multi-organ benefit, so sacubitril valsartan sodium tablets in the treatment of hypertension has been recommended by the key, the market capacity is expanding. Relevant statistics show that in the first half of last year, the domestic market sales of sacubitril valsartan sodium tablets totaled 2.382 billion yuan, and the annual impact is expected to be 4.7 billion yuan.
Against this background, market recognition of Yixintan has also grown steadily since it was approved for marketing.By the end of last year, Yixintan has entered more than 5,000 medical terminals of various types, with total sales of more than 100 million tablets, which is equivalent to saving more than 50 million yuan in drug costs for health insurance and patients.
"Every city has its own character of development.The pharmaceutical industry has always been Nanjing's advantageous industry. Yixintan is locally developed and locally mass-produced, and is authentically 'Made in Nanjing'.The continuous growth of orders since the beginning of this year has laid a solid foundation for Littell's 'open door' in the first quarter, and has given us stronger confidence in 'Made in Nanjing' to benefit more patients." Fangsheng and Chairman Yuan Fang said.
